Format

Send to

Choose Destination
Leuk Lymphoma. 2019 Jun;60(6):1354-1369. doi: 10.1080/10428194.2018.1546854. Epub 2019 Jan 17.

Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

Author information

1
a Section of Hematology, Department of Internal Medicine , Yale University School of Medicine , New Haven , CT , USA.
2
b Division of Hematologic Malignancies, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Abstract

The 5-year overall survival rate of AML patients remains 25-40%. The prognosis is even more dismal for older patients who are ineligible for intensive chemotherapy and patients with secondary or relapsed/refractory AML. In 2017, 4 new drugs were approved by the US Food and Drug Administration for AML treatment: The FLT3 inhibitor midostaurin, the isocitrate dehydrogenase (IDH)-2 inhibitor enasidenib, a liposomal formulation of cytarabine and daunorubicin (CPX-351), and the anti-CD33 antibody gemtuzumab ozogamicin. Additionally, the IDH1 inhibitor ivosidenib has received FDA approval in July 2018. However, all these drugs were approved in certain settings and/or for certain subsets of AML patients. Herein, we review the mechanisms of actions and preclinical data, highlight pivotal clinical trial data, and discuss future directions and challenges for further development of these 5 novel therapeutics. Finally, we briefly overview some of the highly promising agents that are currently in advanced stages of clinical development.

KEYWORDS:

inhibitor; Acute myelogenous leukemia; epigenetic therapy; future directions; novel therapies; targeted therapy

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center